X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215623
https://www.prnewswire.com/news-releases/pulmatrix-announces-positive-top-line-results-from-a-phase-1-study-with-pur3100-a-novel-orally-inhaled-dihydroergotamine-dhe-for-acute-migraine-301712908.html
https://www.fiercepharma.com/pharma/satsuma-peels-fresh-strip-long-term-migraine-study-data-ahead-planned-fda-filing
https://www.globenewswire.com/news-release/2022/08/15/2498198/0/en/Impel-Pharmaceuticals-Announces-Second-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2022/01/18/2368445/0/en/Impel-NeuroPharma-Provides-Updates-on-Trudhesa-Launch-and-Recent-Business-Highlights.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214105
https://www.prnewswire.com/news-releases/cyrano-therapeutics-announces-the-appointment-of-john-kollins-to-its-board-of-directors-301420237.html
https://www.globenewswire.com/news-release/2021/10/12/2312990/0/en/Satsuma-Pharmaceuticals-Announces-the-Appointment-of-Mutya-Harsch-to-its-Board-of-Directors.html
https://www.globenewswire.com/news-release/2021/09/28/2304465/0/en/Impel-NeuroPharma-Announces-Trudhesa-Dihydroergotamine-Mesylate-Nasal-Spray-is-Now-Available-for-Prescription-for-the-Acute-Treatment-of-Migraine.html
https://www.raps.org/news-and-articles/news-articles/2021/9/fda-approvals-roundup-trudhesa-brukinsa-keytruda
https://www.globenewswire.com/news-release/2021/06/22/2251349/0/en/Satsuma-Pharmaceuticals-to-Present-at-SVB-Leerink-s-CNS-Forum.html
https://www.businesswire.com/news/home/20210607005031/en/Amneal-Announces-Dihydroergotamine-DHE-Autoinjector-NDA-for-Migraines-and-Cluster-Headaches
https://www.globenewswire.com/news-release/2020/08/06/2074546/0/en/Satsuma-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-the-ASCEND-Phase-3-open-label-safety-trial-of-STS101.html#:~:text=%E2%80%9CWe%20are%20pleased%20to%20have,President%20and%20Chief%20Executive%20Officer.&text=The%20primary%20objective%20of%20the,needed%20acute%20treatment%20for%20migraine.
https://www.globenewswire.com/news-release/2020/01/28/1976390/0/en/Satsuma-Pharmaceuticals-Announces-Publication-of-STS101-Phase-1-Clinical-Trial-Results-in-HEADACHE-The-Journal-of-Head-and-Face-Pain.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206863
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206621
Market Place
Share 
